Low Mechanical Index Contrast-Enhanced Ultrasound Better Reflects High Arterial Perfusion of Liver Metastases Than Arterial Phase Computed Tomography

2004 ◽  
Vol 39 (4) ◽  
pp. 216-222 ◽  
Author(s):  
Martin Krix ◽  
Fabian Kiessling ◽  
Marco Essig ◽  
Felix Herth ◽  
Andreas Karcher ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Liver Metastases ◽  
Arterial Phase ◽  
Mechanical Index ◽  
Contrast Enhanced Ultrasound ◽  
Arterial Perfusion ◽  
Contrast Enhanced ◽  
Index Contrast

The Feasibility of Low Mechanical Index Contrast Enhanced Ultrasound (CEUS) in Distinguishing Malignant from Benign Thoracic Lesions

2011 ◽  
Vol 37 (11) ◽  
pp. 1747-1754 ◽  
Author(s):  
Nagmi R. Qureshi ◽  
Christian Hintze ◽  
Frank Risse ◽  
Annette Kopp-Schneider ◽  
Ralf Eberhardt ◽  
...  
Keyword(s):  
Mechanical Index ◽  
Contrast Enhanced Ultrasound ◽  
Contrast Enhanced ◽  
Index Contrast

scholarly journals Contrast Enhanced Ultrasound in the Diagnosis and Evaluation of the Efficiency of Chemotherapy in Patients with Colorectal Liver Metastases

2021 ◽  
Vol 101 (6) ◽  
pp. 324-332
Author(s):  
E. V. Kovaleva ◽  
G. T. Sinyukova ◽  
T. Yu. Danzanova ◽  
P. I. Lepedatu ◽  
E. A. Gudilina ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Arterial Phase ◽  
Contrast Enhanced Ultrasound ◽  
Time Curve ◽  
Entire Volume ◽  
Contrast Enhanced ◽  
Group 2 ◽  
Group 1

Objective: to determine the possibilities of contrast-enhanced ultrasound (CEUS) in identifying and evaluating the efficiency of chemotherapy in patients with colorectal liver metastases (CLM).Material and methods. The investigation enrolled 28 patients with CLM. The patients were divided into two groups: Group 1 – 15 pretreatment patients; Group 2 – 13 posttreatment patients with process stabilization. All the patients underwent standard B-mode ultrasound of the liver and that using the contrast agent SonoVue ® (Bracco, Italy), by recording and estimating the parameters of the intensity-time curve (CIV). Liver CEUS assesses the nature of contrasting metastases in three phases (arterial, venous, and delay ones).Results. The investigators identified three types of contrast agent accumulation in CLM in the arterial phase: along the periphery of the lesions (in 60% of the patients of Group 1, in 76.9% in Group 2), homogeneously over the entire volume (in 26.7% in Group 1 and in 0.08% in Group 2), in parallel with intact liver parenchyma (13.3% in Group 1 and 23.02% in Group 2). In the delay phase, more metastases were detected in 4 cases (14.3%). Estimation of CIV parameters showed a difference at the beginning of contrast enhancement stages between the patients in both groups. Group 1 exhibited the early contrasting of liver metastases (19.3 sec); Group 2 displayed the late washout of a contrast agent (65.9 sec).Conclusion. CEUS versus B-mode ultrasound improves the imaging of liver metastases. The change in the vascular architectonics and hemodynamics in CLM after chemotherapy is reflected in the alteration of the rate of contrast accumulation and washout from the metastases, which allows CEUS to be used in the evaluation of the efficiency of this treatment.

scholarly journals Contrast-enhanced ultrasound for the assessment of focal nodular hyperplasia – results of a multicentre study

2021 ◽  
Author(s):  
Roxana Şirli ◽  
Ioan Sporea ◽  
Alina Popescu ◽  
Mirela Dănilă ◽  
Daniela Larisa Săndulescu ◽  
...  
Keyword(s):  
Focal Nodular Hyperplasia ◽  
Predictive Value ◽  
De Novo ◽  
Arterial Phase ◽  
Mechanical Index ◽  
Contrast Enhanced Ultrasound ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct ◽  
Nodular Hyperplasia

Aim: Contrast-enhanced ultrasound (CEUS) has become a relevant imaging method for the evaluation of focal liver le-sions (FLL). The aim of this study was to evaluate the performance of CEUS for the assessment of focal nodular hyperplasia (FNH) in a large study group. Material and methods: We performed a multicentre prospective observational study, which included successive CEUS examinations from fourteen Romanian centres. CEUS examinations were performed in de novo FLL, using low mechanical index ultrasound, following an intravenous bolus of 2.4 ml SonoVue. CEUS was considered conclusive for FNH if a typical pattern was present following contrast (rapid “spoke-wheel” enhancement during the arterial phase, hyperenhanced lesion during venous phase, hyper- or isoenhanced in the late phase). In all cases a reference method was available (contrast enhanced CT or MRI or biopsy). The trial was registered in clinicaltrials.gov (Identifier NCT01329458). Results: During the 6 years study, 2062 “de novo” FLL were evaluated by CEUS. From this cohort, 94/2062 (4.5%) had a typical enhancing pattern for FNH as described in the EFSUMB guidelines. Contrast enhanced CT/MRI and biopsy diagnosed additional 15 FNH. From the 94 cases diagnosed as FNH by CEUS, in nine the final diagnosis was different (five of them adenomas). CEUS had 85% sensitivity, 99.5% specificity, 90.4% positive predictive value, 99.2% negative predictive value and 98.8% diagnostic accuracy for the diagnosis of FNH. Conclusions: CEUS is a sensitive and very specific method for the diagnosis of FNH.

Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis

2021 ◽  
pp. 1-17
Author(s):  
Yanling Chen ◽  
Wenping Wang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Diagnostic Accuracy ◽  
Publication Bias ◽  
Likelihood Ratio ◽  
Intrahepatic Cholangiocarcinoma ◽  
Cochrane Library ◽  
Arterial Phase ◽  
Contrast Enhanced Ultrasound ◽  
Diagnostic Ability ◽  
Contrast Enhanced

AIM: To explore the diagnostic ability of contrast-enhanced ultrasound (CEUS) in distinguishing intrahepatic cholangiocarcinoma (ICC) from hepatocellular carcinoma (HCC). MATERIALS AND METHODS: PubMed, EMBASE, Cochrane Library, and Web of Science were systematically searched for studies reporting the diagnostic accuracy of CEUS in differentiating ICC from HCC. The diagnostic ability of CEUS was assessed based on the pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and area under the curve (AUC) with 95% confidence intervals (CIs). The methodologic quality was assessed by the QUADAS-2 tool. Subgroup analyses, meta-regression and investigation of publication bias were performed to identify the source of heterogeneity. RESULTS: A total of eight studies were included, consisting of 1,116 patients with HCC and 529 with ICC. The general diagnostic performance of CEUS in distinguishing ICC and HCC were as follows: pooled sensitivity, 0.92 (95% CI: 0.84–0.96); pooled specificity, 0.87 (95% CI: 0.79–0.92); pooled PLR, 7.1 (95% CI: 4.1–12.0); pooled NLR, 0.09 (95% CI: 0.05–0.19); pooled DOR, 76 (95% CI: 26–220) and AUC, 0.95(95% CI: 0.93–0.97). Different liver background may be a potential factor that influenced the diagnostic accuracy of CEUS according to the subgroup analysis, with the pooled DOR of 89.67 in the mixed liver background group and 46.87 in the cirrhosis group, respectively. Six informative CEUS features that may help differentiate HCC from ICC were extracted. The three CEUS features favoring HCC were arterial phase hyperenhancement(APHE), mild washout and late washout (>60s); the three CEUS favoring ICC were arterial rim enhancement, marked washout and early washout(<60s). No potential publication bias was observed. CONCLUSION: CEUS showed great diagnostic ability in differentiating ICC from HCC, which may be promising for noninvasive evaluation of these diseases.

Sign in / Sign up

Export Citation Format

Share Document